The oncology-focused company confirmed after Tuesday's market close that the capital raised would be directed toward research and development pipelines, alongside general corporate expenses and working capital requirements. This move signals a significant push to stabilize the company's cash reserves, though shareholders responded by retreating from the stock throughout the Wednesday session.
In section Market Quotes
Summit Therapeutics Shares Hit Yearly Low After $500 Million Offering
Investors pushed Summit Therapeutics to a 52-week low on Wednesday following the company's announcement of a $500 million secondary stock offering. The share price dropped 11% to $12.67 by early afternoon, deepening the biopharmaceutical firm's annual decline to 27% as the market reacted to the impending equity dilution.
Comments (0)
No comments yet. Be the first!